A case of severe opioid and methamphetamine use disorder in a 14 year old.


Journal

Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 22 01 2024
accepted: 08 07 2024
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 19 7 2024
Statut: epublish

Résumé

We present the case of a 14-year-old who established care at our primary care clinic after hospitalization for unintentional fentanyl overdose. They were diagnosed with severe opioid use disorder (OUD) and stimulant use disorder (StUD) and initiated buprenorphine while inpatient. They were then transitioned to the only known outpatient primary care clinic in her county who was actively providing medications for opioid use disorder (MOUD) in adolescents.At the first visit, they reported a history of 20 overdoses, struggling with adherence to buprenorphine and continued opioid cravings. An overdose safety plan was reviewed with them and their parent including providing them naloxone kits, fentanyl test strips, and education handout sheets. Due to their significant overdose history and adherence challenges with sublingual buprenorphine, they were started on long-acting injectable buprenorphine (LAIB) with weekly provider visits and urine toxicology screening. In collaboration with the treatment team, they initiated behavioral treatment with contingency management (CM), with incentives for appointment completion, expected urine results, and successful medication administration. Over the next 19 months, and to date, they have increasingly engaged with care and have remained abstinent. LAIB may be an appealing alternative for adolescents with OUD to improve adherence and reduce risk of recurrent use and overdose. Adjunctive treatment with CM may improve retention in MOUD and have the benefit of treating StUD. There is a need for further research to explore innovative, community-based treatment for youth with OUD.

Identifiants

pubmed: 39030629
doi: 10.1186/s13722-024-00487-1
pii: 10.1186/s13722-024-00487-1
doi:

Substances chimiques

Buprenorphine 40D3SCR4GZ
Narcotic Antagonists 0
Methamphetamine 44RAL3456C
Fentanyl UF599785JZ

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54

Informations de copyright

© 2024. The Author(s).

Références

Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in Drug Overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022;327(14):1398–400.
doi: 10.1001/jama.2022.2847 pubmed: 35412573 pmcid: 9006103
Lim JK, Earlywine JJ, Bagley SM, Marshall BDL, Hadland SE. Polysubstance involvement in opioid overdose deaths in adolescents and young adults, 1999–2018. JAMA Pediatr. 2021;175(2):194–6.
doi: 10.1001/jamapediatrics.2020.5035 pubmed: 33226412
Robinson CA, Wilson JD. Management of Opioid Misuse and Opioid Use disorders among Youth. Pediatrics. 2020;145(Suppl 2):S153–64.
doi: 10.1542/peds.2019-2056C pubmed: 32358206
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of medications in the treatment of Addiction Involving Opioid Use. J Addict Med. 2015;9(5):358–67.
doi: 10.1097/ADM.0000000000000166 pubmed: 26406300 pmcid: 4605275
Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid Use disorders. Pediatrics. 2016;138(3):e20161893.
doi: 10.1542/peds.2016-1893
Hadland SE, Aalsma MC, Akgül S, Alinsky RH, Bruner A, Chadi N, et al. Medication for adolescents and young adults with opioid Use Disorder. J Adolesc Health off Publ Soc Adolesc Med. 2021;68(3):632–6.
doi: 10.1016/j.jadohealth.2020.12.129
AACAP. Opioid Use Disorder Treatment for Youth. [cited 2024 May 24]. https://www.aacap.org/AACAP/Policy_Statements/2020/Opioid_Use_Disorder_Treatment_Youth.aspx .
Terranella A, Guy GP, Mikosz C. Buprenorphine Dispensing among Youth aged ≤ 19 years in the United States: 2015–2020. Pediatrics. 2023;151(2):e2022058755.
doi: 10.1542/peds.2022-058755 pubmed: 36691760
Bolívar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency management for patients receiving medication for opioid use disorder: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(10):1092–102.
doi: 10.1001/jamapsychiatry.2021.1969 pubmed: 34347030
Stanger C, Budney AJ. Contingency management: using incentives to improve outcomes for adolescent substance Use disorders. Pediatr Clin North Am. 2019;66(6):1183–92.
doi: 10.1016/j.pcl.2019.08.007 pubmed: 31679606 pmcid: 6834344
Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addict Abingdon Engl. 2006;101(11):1546–60.
doi: 10.1111/j.1360-0443.2006.01581.x
Hadland SE, Burr WH, Zoucha K, Somberg CA, Camenga DR. Treating adolescent opioid Use Disorder in Primary Care. JAMA Pediatr. 2024;178(4):414–6.
doi: 10.1001/jamapediatrics.2023.6493 pubmed: 38407892

Auteurs

Nadia Allami (N)

Santa Cruz Community Health, 1510 Capitola Road, Santa Cruz, CA, 95062, USA. Allami.nadia@gmail.com.

Kristen O'Connor (K)

Santa Cruz Community Health, 1510 Capitola Road, Santa Cruz, CA, 95062, USA.

Sarah M Bagley (SM)

Chobanian & Avedisian School of Medicine and Boston Medical Center, 801 Mass Ave, Boston, MA, 02118, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH